The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy of INK128, an mTORC1/mTORC2 kinase inhibitor, in breast cancer models driven by HER2-PI3K-AKT-mTOR pathway.
Pradip De
No relevant relationships to disclose
Yuliang Sun
No relevant relationships to disclose
Hui Wu
No relevant relationships to disclose
Christian Rommel
No relevant relationships to disclose
Yi Liu
No relevant relationships to disclose
Nandini Dey
No relevant relationships to disclose
Brian Leyland-Jones
No relevant relationships to disclose